AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25199824 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation Therapy (SMT)
Number of subjects: 0
Study 25199824 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Exercise and Advice (HEA)
Number of subjects: 0
Study 25199824 — intervention group
Group type: COMPARATOR
Intervention: Medication (MED)
Number of subjects: 0
Study 22231041 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin
Number of subjects: 49
Study 22231041 — intervention group
Group type: COMPARATOR
Intervention: Control (no triptorelin)
Number of subjects: 49
Study 20576763 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% topical ciclosporin A
Number of subjects: 43
Study 20576763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 17915119 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal reminder on tetanus vaccination
Number of subjects: 622
Study 17915119 — intervention group
Group type: COMPARATOR
Intervention: No action (control group)
Number of subjects: 622
Study 15663445 — intervention group
Group type: EXPERIMENTAL
Intervention: slow‐speed bur and acid etching
Number of subjects: 128
Study 15663445 — intervention group
Group type: EXPERIMENTAL
Intervention: air abrasion and acid etching
Number of subjects: 128
Study 15663445 — intervention group
Group type: EXPERIMENTAL
Intervention: acid etching and application of a bonding agent
Number of subjects: 128
Study 15663445 — intervention group
Group type: COMPARATOR
Intervention: slow‐speed prophylaxis brush followed by acid etching (control method)
Number of subjects: 128
Study 12244290 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg/kg and Ketamine 2 mg/kg (MK2)
Number of subjects: 120
Study 12244290 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg/kg and Ketamine 1 mg/kg (MK1)
Number of subjects: 120
Study 12244290 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.5 mg/kg (Control group M)
Number of subjects: 120
Study 10397661 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% acyclovir in a novel liposomal carrier (ethosome)
Number of subjects: 40
Study 10397661 — intervention group
Group type: COMPARATOR
Intervention: 5% acyclovir cream (Zovirax cream)
Number of subjects: 40
Study 10397661 — intervention group
Group type: COMPARATOR
Intervention: Drug-free vehicle
Number of subjects: 40
Study 7577164 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest for five days
Number of subjects: 9
Study 2271366 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (100-400 mg daily)
Number of subjects: 19
Study 2271366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 389818 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g sulphamethizole twice daily
Number of subjects: 1194
Study 389818 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg trimethoprim twice daily
Number of subjects: 1194
Study 389818 — intervention group
Group type: EXPERIMENTAL
Intervention: 410 mg sulphadiazine plus 90 mg trimethoprim twice daily
Number of subjects: 1194
Study 389818 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 1194
Study 389818 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg trimethoprim alone
Number of subjects: 1194
Study 389818 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g sulphamethizole
Number of subjects: 1194
Study 389818 — intervention group
Group type: EXPERIMENTAL
Intervention: 410 mg sulphadiazine plus 90 mg trimethoprim
Number of subjects: 1194
Study 30869200 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP adherence reported via CASI
Number of subjects: 130
Study 30869200 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors facilitating adherence
Number of subjects: 130
Study 30869200 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence barriers
Number of subjects: 130
Study 30869200 — intervention group
Group type: EXPERIMENTAL
Intervention: Future use intentions of PrEP
Number of subjects: 130
Study 29016653 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU/day vitamin D3 supplementation
Number of subjects: 32
Study 29016653 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU/day vitamin D3 supplementation
Number of subjects: 32
Study 25504811 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic disease‐modifying antirheumatic drugs (DMARDs)
Number of subjects: 0
Study 23688525 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 100
Study 23688525 — intervention group
Group type: COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Number of subjects: 100
Study 23688525 — intervention group
Group type: EXPERIMENTAL
Intervention: PPSV23 after initial PCV13
Number of subjects: 100
Study 23688525 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 (re-vaccination for all adults aged 50-59)
Number of subjects: 100
Study 21357275 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan 100 mg once daily
Number of subjects: 27
Study 21357275 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 30 mg once daily
Number of subjects: 27
Study 21357275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 19134171 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone counselling
Number of subjects: 1386
Study 19134171 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail counselling
Number of subjects: 1386
Study 19134171 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1386
Study 17335962 — intervention group
Group type: EXPERIMENTAL
Intervention: Active magnetic stimulation (Neocontrol), 20 treatments of 20 minutes each over six weeks.
Number of subjects: 44
Study 17335962 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (identical looking/sounding device with deflector plate), 20 treatments of 20 minutes each over six weeks.
Number of subjects: 44
Study 17335962 — intervention group
Group type: EXPERIMENTAL
Intervention: Active magnetic stimulation during cystometry.
Number of subjects: 44
Study 14764129 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal electrical stimulation (TES)
Number of subjects: 36
Study 14764129 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical equipment but with no electrical current)
Number of subjects: 36
Study 11301931 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment educational model
Number of subjects: 15
Study 11301931 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing educational model
Number of subjects: 15
Study 11301931 — intervention group
Group type: EXPERIMENTAL
Intervention: Helping People to Change educational model
Number of subjects: 15
Study 9308642 — intervention group
Group type: COMPARATOR
Intervention: Standard blood components (not screened for CMV antibody)
Number of subjects: 76
Study 9308642 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV-seronegative red cell (RBC) and platelet units
Number of subjects: 76
Study 7959579 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (cisplatinum and 5-fluorouracil) and radiation followed by resection
Number of subjects: 69
Study 7959579 — intervention group
Group type: COMPARATOR
Intervention: Resection alone
Number of subjects: 69
Study 3311054 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate (200 mg t.i.d.)
Number of subjects: 40
Study 3311054 — intervention group
Group type: COMPARATOR
Intervention: colestyramine (4 g t.i.d.)
Number of subjects: 40
Study 31559844 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial therapy (1 session per week for 3 weeks)
Number of subjects: 65
Study 31559844 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 65
Study 31559844 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial therapy
Number of subjects: 65
Study 31559844 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 29530259 — intervention group
Group type: EXPERIMENTAL
Intervention: IBM targeting hostile interpretation bias (IBM‐H)
Number of subjects: 40
Study 29530259 — intervention group
Group type: COMPARATOR
Intervention: Healthy video control (HVC)
Number of subjects: 40
Study 28483774 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 0
Study 28483774 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tissue plasminogen activator (IV tPA) alone
Number of subjects: 0
Study 25629321 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 8 mg (DexIV)
Number of subjects: 75
Study 25629321 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone 8 mg (DexP)
Number of subjects: 75
Study 25629321 — intervention group
Group type: COMPARATOR
Intervention: Control (30-mL bupivacaine 0.5% alone)
Number of subjects: 75
Study 25629321 — intervention group
Group type: EXPERIMENTAL
Intervention: DexIV and DexP
Number of subjects: 75
Study 23566943 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (7000 IU daily for 26 weeks)
Number of subjects: 52
Study 23566943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 20931100 — intervention group
Group type: EXPERIMENTAL
Intervention: LOS 150 mg/HCTZ 25 mg
Number of subjects: 105
Study 20931100 — intervention group
Group type: EXPERIMENTAL
Intervention: LOS 150 mg/HCTZ 37.5 mg
Number of subjects: 105
Study 18222735 — intervention group
Group type: EXPERIMENTAL
Intervention: Goshuyuto extract for 1 month, followed by 3 months of goshuyuto in the treatment group.
Number of subjects: 0
Study 18222735 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months in the control group.
Number of subjects: 0
Study 15973834 — intervention group
Group type: EXPERIMENTAL
Intervention: CSEB applied without any cavity preparation
Number of subjects: 34
Study 15973834 — intervention group
Group type: EXPERIMENTAL
Intervention: CSEB applied after beveling enamel
Number of subjects: 34
Study 15973834 — intervention group
Group type: EXPERIMENTAL
Intervention: CSEB applied after etching enamel for 15 seconds with 35% phosphoric acid
Number of subjects: 34
Study 15973834 — intervention group
Group type: EXPERIMENTAL
Intervention: CSEB applied after beveling and etching enamel
Number of subjects: 34
Study 15973834 — intervention group
Group type: COMPARATOR
Intervention: Overall results pooled from all groups
Number of subjects: 34
Study 12796137 — intervention group
Group type: EXPERIMENTAL
Intervention: 22.5 Gy intravascular beta‐irradiation with rhenium-188 (n=113)
Number of subjects: 225
Study 12796137 — intervention group
Group type: COMPARATOR
Intervention: No additional intervention (n=112)
Number of subjects: 225
Study 10641044 — intervention group
Group type: EXPERIMENTAL
Intervention: Taiga Wurzel (ergospirometric study)
Number of subjects: 50
Study 8846291 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (S group, n = 10)
Number of subjects: 19
Study 8846291 — intervention group
Group type: COMPARATOR
Intervention: Halothane (H group, n = 9)
Number of subjects: 19
Study 1506461 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined education and stress management program
Number of subjects: 81
Study 1506461 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study 6728094 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (30 micrograms/kg bodyweight/hour intravenously for 10 days, then orally for 4 days in diminishing dosages)
Number of subjects: 27
Study 6728094 — intervention group
Group type: COMPARATOR
Intervention: Control group (9 patients not given Nimodipine)
Number of subjects: 27
Study 31622292 — intervention group
Group type: EXPERIMENTAL
Intervention: Rush pin with long arm cast (Group B)
Number of subjects: 60
Study 31622292 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Compression Plate (Group A)
Number of subjects: 60
Study 28499016 — intervention group
Group type: EXPERIMENTAL
Intervention: Banana-shaped cage
Number of subjects: 84
Study 28499016 — intervention group
Group type: COMPARATOR
Intervention: Straight cage
Number of subjects: 84
Study 26901353 — intervention group
Group type: EXPERIMENTAL
Intervention: 840 mg/day DHA
Number of subjects: 300
Study 26901353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 25105388 — intervention group
Group type: EXPERIMENTAL
Intervention: CS/PADM
Number of subjects: 80
Study 25105388 — intervention group
Group type: COMPARATOR
Intervention: Conventional bridged VHR
Number of subjects: 80
Study 22569072 — intervention group
Group type: EXPERIMENTAL
Intervention: [¹⁵N]WP, [¹³C]Cas, and lactose
Number of subjects: 18
Study 22569072 — intervention group
Group type: EXPERIMENTAL
Intervention: [¹³C]WP, [¹⁵N]Cas, and lactose
Number of subjects: 18
Study 22569072 — intervention group
Group type: COMPARATOR
Intervention: lactose alone
Number of subjects: 18
Study 19148407 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% titanium tetrafluoride solution (TiF4)
Number of subjects: 10
Study 19148407 — intervention group
Group type: COMPARATOR
Intervention: Control (no TiF4)
Number of subjects: 10
Study 17444584 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg
Number of subjects: 6
Study 17444584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 16153511 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain echocardiography
Number of subjects: 0
Study 16153511 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and hypertension
Number of subjects: 0
Study 11823759 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg
Number of subjects: 24
Study 11823759 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg
Number of subjects: 24
Study 11823759 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Number of subjects: 24
Study 11823759 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 24
Study 11823759 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 24
Study 11823759 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg
Number of subjects: 24
Study 10069545 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) 50 mg
Number of subjects: 51
Study 10069545 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 51
Study 9805071 — intervention group
Group type: EXPERIMENTAL
Intervention: Heberbiovac-HB vaccine at 10 g
Number of subjects: 3
Study 9805071 — intervention group
Group type: EXPERIMENTAL
Intervention: Heberbiovac-HB vaccine at 5 g
Number of subjects: 3
Study 9805071 — intervention group
Group type: EXPERIMENTAL
Intervention: Heberbiovac-HB vaccine at 2.5 g
Number of subjects: 3
Study 9805071 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall reactogenicity for all groups
Number of subjects: 3
Study 9805071 — intervention group
Group type: EXPERIMENTAL
Intervention: Predominant symptoms
Number of subjects: 3
Study 2032492 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous LAK cell reinfusion treatment for 6 weeks
Number of subjects: 64
Study 2032492 — intervention group
Group type: COMPARATOR
Intervention: 10% glucose solution intravenous drip for 6 weeks
Number of subjects: 64
Study 7226903 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose theophylline
Number of subjects: 18
Study 7226903 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (10 mg)
Number of subjects: 18
Study 7226903 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose theophylline (130 mg)
Number of subjects: 18
Study 7226903 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose theophylline (130 mg) + fenoterol (5 mg)
Number of subjects: 18
Study 7226903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31827346 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex response time (CRT) protocol
Number of subjects: 47
Study 31827346 — intervention group
Group type: COMPARATOR
Intervention: Simple response time (SRT) tests
Number of subjects: 47
Study 30082324 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted sitting (3 min of moderate-intensity walking at 80% of ventilatory threshold every 30 min for 3 h)
Number of subjects: 35
Study 30082324 — intervention group
Group type: COMPARATOR
Intervention: Prolonged sitting (3 h of continuous sitting)
Number of subjects: 35
Study 26609969 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex Contrast Training (CCT); N=10
Number of subjects: 22
Study 26609969 — intervention group
Group type: COMPARATOR
Intervention: Traditional Strength Training (TST); N=12
Number of subjects: 22
Study 24606865 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13/PPSV23
Number of subjects: 720
Study 24606865 — intervention group
Group type: EXPERIMENTAL
Intervention: PPSV23/PCV13
Number of subjects: 720
Study 24606865 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13/PCV13
Number of subjects: 720
Study 24606865 — intervention group
Group type: COMPARATOR
Intervention: PPSV23
Number of subjects: 720
Study 22442396 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 22442396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19081652 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: Paclitaxel 200 mg/m2 and carboplatin AUC6 with accelerated radiotherapy 1.7 Gy BID to 64.6 Gy in 4.5 weeks.
Number of subjects: 151
Study 19081652 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B: Daily concomitant paclitaxel 12 mg/m2 with conventionally fractionated radiotherapy 2 Gy to 60 Gy in 6 weeks.
Number of subjects: 151
Study 19081652 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm C: Weekly concomitant paclitaxel 60 mg/m2 and identical radiotherapy to 60 Gy.
Number of subjects: 151
Study 19081652 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified as there are three treatment arms.
Number of subjects: 151
Study 17868210 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled extract of Nigella sativa (15 mL/kg of 0.1 g%)
Number of subjects: 29
Study 17868210 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 29
Study 15115259 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of vitamin B6 daily and one monthly injection of 200 microg vitamin B12, plus 15 mg folic acid daily (group A)
Number of subjects: 50
Study 15115259 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of vitamin B6 daily and one monthly injection of 1,000 microg vitamin B12, plus 15 mg folic acid daily (group B)
Number of subjects: 50
Study 11873639 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of drains on 2nd postoperative day
Number of subjects: 100
Study 11873639 — intervention group
Group type: COMPARATOR
Intervention: Removal of drains on 3rd postoperative day
Number of subjects: 100
Study 9922064 — intervention group
Group type: EXPERIMENTAL
Intervention: Community outreach intervention conducted by indigenous lay health workers; 56 sessions on general prevention, 86 on cervical cancer, and 90 on breast cancer.
Number of subjects: 373
Study 9922064 — intervention group
Group type: COMPARATOR
Intervention: Control group (women in Sacramento, California)
Number of subjects: 373
Study 7483616 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (magnesium carbonate) 3 x 0.6
Number of subjects: 60
Study 7483616 — intervention group
Group type: EXPERIMENTAL
Intervention: Proajmaline (neogilurytmal) 3 x 20 mg
Number of subjects: 60
Study 7483616 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (neogilurytmal 2 x 20 mg and magnesium 2 x 0.6)
Number of subjects: 60
Study 7483616 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 3190993 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 50 mg daily
Number of subjects: 8
Study 3190993 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 100 mg daily
Number of subjects: 8
Study 3190993 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg daily
Number of subjects: 8
Study 3190993 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 600 mg daily
Number of subjects: 8
Study 3190993 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (various doses)
Number of subjects: 8
Study 3190993 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (cessation)
Number of subjects: 8
Study 123426 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocytic interferon with metacyl (0.25 ml once a day)
Number of subjects: 213
Study 123426 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocytic interferon with metacyl
Number of subjects: 213
Study 31903299 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound Conforming Matrix (WCM)
Number of subjects: 100
Study 31903299 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 100
Study 31076203 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 μg of nemiralisib via Ellipta dry powder inhaler
Number of subjects: 12
Study 31076203 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 μg of nemiralisib via Ellipta dry powder inhaler
Number of subjects: 12
Study 29387128 — intervention group
Group type: EXPERIMENTAL
Intervention: Gongjindan (GJD) 3.75g orally once a day for 56 days
Number of subjects: 78
Study 29387128 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3.75g orally once a day for 56 days)
Number of subjects: 78
Study 29387128 — intervention group
Group type: EXPERIMENTAL
Intervention: Gongjindan (GJD)
Number of subjects: 78
Study 29387128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 26964165 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and isolated-ginger moxibustion
Number of subjects: 110
Study 26964165 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (0.2 mg, twice a day for 1 month)
Number of subjects: 110
Study 22924409 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg once daily for 5 days (n = 48)
Number of subjects: 72
Study 22924409 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 24)
Number of subjects: 72
Study 22924409 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg administered 24 h post-warfarin
Number of subjects: 72
Study 22099889 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Dads, Healthy Kids program
Number of subjects: 50
Study 22099889 — intervention group
Group type: COMPARATOR
Intervention: 6-month wait-list control group
Number of subjects: 50
Study 18294998 — intervention group
Group type: EXPERIMENTAL
Intervention: Idraparinux (2.5 mg weekly)
Number of subjects: 4576